Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Ivacaftor in Cystic Fibrosis Patients Homozygous for F508del
2009-010261-23Phase 2
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing Ivacaftor with Placebo (2 arms). Primary endpoint: Absolute change in percent predicted FEV1 from baseline through Week 16.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2009-010261-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010261-23.